Litigation Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2022)

« Back to Dashboard

Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2022)

Docket	1:22-cv-00182	Date Filed	2022-02-09
Court	District Court, D. Delaware	Date Terminated	2023-10-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,229,627
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-02-09				External link to document

Allergan USA v. Sun Pharmaceutical Industries: Vraylar Patent Litigation Summary, Case No. 1:22-cv-00182

Last updated: October 14, 2026

Allergan USA, Inc. sued Sun Pharmaceutical Industries Limited in the U.S. District Court for the District of Delaware after Sun filed an abbreviated new drug application seeking approval to market generic cariprazine hydrochloride capsules, the active ingredient in Vraylar. The case was a Hatch-Waxman patent action based on Sun’s Paragraph IV certifications against Allergan’s Orange Book-listed Vraylar patents. The litigation covered formulation and treatment patents rather than a biosimilar product.

The principal commercial issue was whether Sun could launch generic cariprazine before expiration of Allergan’s listed patent rights. The case was resolved through a settlement and dismissal, with the commercial launch date and other terms not publicly disclosed in the court docket.

What drug and ANDA were involved in Allergan USA v. Sun Pharmaceutical?

The case involved Vraylar, a prescription capsule containing cariprazine hydrochloride.

Item	Information
Reference product	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
Therapeutic area	Schizophrenia and bipolar disorder
NDA holder	Allergan Pharmaceuticals International Limited and related Allergan entities
U.S. plaintiff	Allergan USA, Inc.
Defendant	Sun Pharmaceutical Industries Limited and related Sun entities
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:22-cv-00182
Filing date	February 10, 2022
Litigation type	Hatch-Waxman ANDA patent litigation
Regulatory pathway	Abbreviated New Drug Application
Product type	Small-molecule generic, not a biosimilar

Vraylar was approved by the FDA for schizophrenia and manic or mixed episodes associated with bipolar I disorder. The FDA later approved additional bipolar-depression indications. The product is part of the atypical antipsychotic market and was developed by Forest Laboratories, which became part of Allergan through the Actavis acquisition.

What patents did Allergan assert against Sun?

Allergan’s complaint alleged infringement of patents listed for Vraylar in the FDA’s Orange Book. The asserted patent group covered cariprazine, pharmaceutical compositions, dosage forms, and methods of treatment.

Public patent records associate Vraylar with a family of cariprazine patents, including the following U.S. patents:

Patent	General subject matter	Relevance to Vraylar
U.S. Patent No. 8,598,233	Cariprazine compounds and related pharmaceutical protection	Core active-ingredient patent family
U.S. Patent No. 8,927,592	Cariprazine-related pharmaceutical claims	Composition and product protection
U.S. Patent No. 9,138,432	Cariprazine compounds and formulations	Product and formulation protection
U.S. Patent No. 9,566,122	Cariprazine pharmaceutical compositions	Orange Book-listed product protection
U.S. Patent No. 10,022,362	Cariprazine-related composition and treatment claims	Later patent-layer protection
U.S. Patent No. 10,925,857	Cariprazine treatment and pharmaceutical claims	Later-expiring Vraylar protection

The exact patents asserted against Sun should be determined from the operative complaint and claim amendments rather than from the broader universe of patents associated with Vraylar. In ANDA cases, a plaintiff may assert only a subset of the patents listed in the Orange Book.

What were Sun’s Paragraph IV allegations?

Sun’s ANDA filing triggered the dispute by certifying that one or more Orange Book-listed Vraylar patents were invalid, unenforceable, or would not be infringed by Sun’s proposed generic product.

A Paragraph IV certification does not establish that a patent is invalid. It creates a statutory basis for the patent owner to sue. If the patent owner files an infringement action within 45 days after receiving the certification notice, FDA approval of the ANDA is generally subject to a 30-month stay, unless the stay is shortened or otherwise terminated by court action.

Sun’s litigation position would have placed the following issues at the center of the case:

1. Whether Sun’s proposed cariprazine capsules met the limitations of the asserted composition or formulation claims.
2. Whether the asserted claims were anticipated or obvious.
3. Whether the asserted patents complied with written-description and enablement requirements.
4. Whether the patents were enforceable.
5. Whether the asserted claims covered the approved Vraylar indications or Sun’s proposed generic labeling.

The public resolution did not produce a merits judgment invalidating the Vraylar patents or finding that Sun infringed them.

When did the Allergan v. Sun Vraylar litigation begin?

Allergan filed the complaint on February 10, 2022, in the District of Delaware under Case No. 1:22-cv-00182. The action followed Sun’s ANDA Paragraph IV notice concerning generic cariprazine capsules.

The filing date is commercially important because it placed the case within the statutory 30-month stay framework. Assuming the notice was received shortly before suit, the stay would ordinarily have extended into approximately mid-2024. The precise FDA stay date depends on the date Allergan received Sun’s Paragraph IV notice and whether any procedural event altered the statutory calculation.

What was the litigation status and outcome?

The case was resolved by settlement rather than by a publicly reported trial judgment. The docket reflects dismissal following settlement, and the settlement’s economic and launch provisions were not publicly disclosed.

Procedural issue	Status
Complaint	Filed February 10, 2022
ANDA dispute	Paragraph IV challenge involving generic cariprazine
Trial judgment	No public merits judgment reported
Settlement	Reached between the parties
Case disposition	Dismissed pursuant to settlement
Settlement terms	Not publicly disclosed
Launch date	Not publicly disclosed
Patent validity ruling	None publicly entered in this action
Patent infringement ruling	None publicly entered in this action

The absence of a merits decision means the case did not generate a binding district-court ruling on the validity, construction, or infringement of the asserted Vraylar patents.

What did the settlement mean for generic Vraylar entry?

The settlement removed Sun from active litigation but did not necessarily authorize immediate generic entry. Hatch-Waxman settlements commonly include a negotiated launch date, restrictions on launch, licensing terms, or other commercial provisions. The public docket did not disclose the operative economic terms.

The settlement therefore has three distinct consequences:

• Sun’s ANDA was no longer being litigated in this action.
• Allergan retained the ability to enforce its patent rights against unauthorized launch.
• The date of Sun’s potential commercial entry cannot be established from the publicly disclosed dismissal alone.

A dismissal pursuant to settlement is not evidence that the patents were upheld or that Sun’s generic product was found non-infringing. It reflects a private resolution of the dispute.

What is the Orange Book status of Vraylar?

Vraylar’s patent protection has been layered across compound, composition, formulation, and method-of-use claims. The Orange Book listing strategy is commercially significant because each listed patent can trigger a Paragraph IV dispute and, if sued upon within the statutory period, contribute to FDA approval delay.

Core patent protection

The foundational Vraylar patent family covers cariprazine and related chemical and pharmaceutical subject matter. These patents provide the main barrier to generic capsule entry where the proposed ANDA product contains the same active ingredient.

Formulation protection

Formulation claims can protect the composition of the capsule even after narrower compound claims face validity or expiration challenges. They may address:

• Cariprazine hydrochloride compositions.
• Specific excipient combinations.
• Dose strengths.
• Pharmaceutical dosage forms.
• Stability or manufacturing characteristics.

Formulation patents are most valuable when the generic applicant cannot design around the claim limitations without changing its proposed ANDA product.

Method-of-use protection

Method-of-use patents can cover treatment of schizophrenia, bipolar mania, mixed episodes, or bipolar depression. Their practical value depends on the scope of the FDA-approved generic label and the ability of the ANDA applicant to use a section viii statement or a label carve-out.

A method patent may not prevent generic approval if the patented indication can be removed from the proposed label and the remaining labeling does not encourage infringement. Product and formulation patents are generally more direct barriers to approval than indication-only patents.

How strong was Allergan’s patent estate?

Allergan’s Vraylar estate was stronger as a layered portfolio than as a single-patent barrier. Its commercial protection depended on the interaction of several patent categories.

Patent layer	Generic-entry impact	Strategic assessment
Active-ingredient claims	High if valid and unexpired	Difficult to design around where the generic must use cariprazine
Composition claims	High to moderate	Depends on claim breadth and the ANDA formulation
Formulation claims	Moderate to high	Can preserve protection after compound challenges
Method-of-use claims	Moderate	Vulnerable to label carve-outs and section viii strategies
Manufacturing claims	Variable	Strong only if the ANDA process practices the claimed steps
Later continuation patents	Potentially high	Can extend litigation and delay commercial certainty

The estate’s principal weakness was the standard vulnerability of pharmaceutical patent families to invalidity challenges based on obviousness, written description, enablement, anticipation, and double-patenting. Continuation patents can extend the period of uncertainty, but they do not guarantee that every claim will survive challenge.

Which companies were challenging Vraylar patents?

Vraylar has been the subject of generic-entry activity involving multiple ANDA applicants, including Sun and other generic manufacturers. The competitive significance of each challenge depends on:

• The applicant’s ANDA filing date.
• The patents identified in its Paragraph IV notice.
• Whether the brand company sued within 45 days.
• Any first-filer or 180-day exclusivity rights.
• The settlement date and negotiated launch provisions.
• Whether the FDA accepted a patent certification or label carve-out.

A settlement with Sun did not eliminate challenges by other generic companies. Each ANDA applicant may have a different litigation posture and may reach a separate settlement with Allergan or its successors.

What is the FDA regulatory status of generic cariprazine?

Sun’s product was an ANDA-based generic version of Vraylar, not a 351(k) biosimilar. FDA approval of the ANDA remained subject to applicable patent certifications, the statutory 30-month stay, any court order, and FDA review of the product’s pharmaceutical equivalence and bioequivalence.

The settlement itself did not constitute FDA approval. Nor did it require FDA approval on a specific date unless the settlement included an agreed launch and approval framework that was separately implemented through the regulatory process.

Vraylar’s regulatory exclusivity and patent exclusivity must be analyzed separately. FDA marketing exclusivity may expire before the relevant patent barriers. Conversely, an unexpired patent may continue to delay or restrict generic entry after regulatory exclusivity has ended.

What litigation risks affected Sun’s potential launch?

Sun faced four principal risks:

1. Infringement risk. Launch before resolution of the asserted patents could expose Sun to damages and injunctive relief.
2. Invalidity risk. A failed Paragraph IV challenge could delay entry until the relevant patents expired.
3. Label risk. A carve-out for patented indications could limit the commercial scope of the generic product.
4. Settlement risk. A negotiated entry date could postpone launch beyond the earliest theoretical date under the patent statute.

Allergan faced corresponding risks. A successful invalidity ruling could have removed a major barrier to generic competition, while a narrow claim construction could have reduced the value of later patent layers.

How did the case compare with biosimilar litigation?

The case was not a biosimilar dispute. It involved a chemically defined small-molecule drug and an ANDA.

Issue	Allergan v. Sun	Biosimilar litigation
Product	Generic cariprazine capsules	Biologic or interchangeable biosimilar
Statute	Hatch-Waxman Act	Public Health Service Act and related patent procedures
Regulatory filing	ANDA	351(k) application
Equivalence standard	Pharmaceutical equivalence and bioequivalence	Biosimilarity or interchangeability
FDA patent listing	Orange Book	No direct Orange Book equivalent for biologic patent listings
Typical dispute	Paragraph IV certification	Patent dance and infringement litigation
Launch dynamics	30-month stay and generic exclusivity	Reference-product exclusivity and biologic patent negotiations

This distinction matters because a settlement analysis for Sun cannot be extrapolated directly to a biosimilar launch or biologic patent estate.

What revenue exposure did generic Vraylar create?

Vraylar was a major commercial product for Allergan and later AbbVie. Generic entry would affect revenue through price erosion, formulary substitution, pharmacy-level substitution, and loss of branded market share.

The economic impact would depend on:

• The number of approved generic applicants at launch.
• Whether Sun received first-filer status.
• The negotiated entry date.
• The number of strengths and indications covered by the generic label.
• Payer substitution policies.
• The timing of additional generic launches.
• The durability of later method-of-use and formulation patents.

A single generic entrant can produce meaningful price pressure, while multiple entrants usually accelerate erosion. The settlement reduced Sun-specific litigation uncertainty but did not remove the broader generic-entry risk to Vraylar.

What geographic protection did the case provide?

The case addressed U.S. patent rights only. The District of Delaware judgment or dismissal had no direct legal effect on cariprazine patents in Europe, Canada, Japan, or other markets.

Global commercial protection would require separate analysis of:

• National patent families.
• Patent term adjustments and supplementary protection certificates.
• Local regulatory exclusivity.
• Generic approvals in each jurisdiction.
• Licensing or settlement agreements outside the United States.
• Manufacturing and supply arrangements.

The U.S. settlement should not be treated as a global license or a worldwide resolution absent express terms.

Key Takeaways

• Allergan USA v. Sun Pharmaceutical Industries, No. 1:22-cv-00182, was a Delaware Hatch-Waxman case concerning generic cariprazine capsules, the active ingredient in Vraylar.
• Allergan sued after Sun filed a Paragraph IV challenge to Vraylar-related Orange Book patents.
• The asserted protection involved cariprazine, pharmaceutical compositions, formulations, and treatment methods.
• The case ended through settlement and dismissal rather than a public trial judgment.
• The settlement terms and Sun’s negotiated launch date were not publicly disclosed.
• The case did not involve a biosimilar, a biologic, or a 351(k) application.
• The resolution removed Sun from active litigation but did not eliminate generic-entry risk from other ANDA applicants.
• No public merits ruling established that the asserted patents were valid, invalid, infringed, or not infringed.

FAQs

Did Sun win the Allergan Vraylar patent case?

No public merits judgment awarded victory to either party. The action was resolved by settlement and dismissed.

Can Sun launch generic cariprazine immediately after the dismissal?

Not necessarily. A settlement dismissal does not by itself establish an immediate launch right. The negotiated entry date and other commercial terms were not publicly disclosed.

Did the case invalidate any Vraylar patent?

No public order in the action invalidated the asserted Vraylar patents.

Does the settlement apply to other generic Vraylar manufacturers?

No. A settlement between Allergan and Sun generally binds the settling parties. Other ANDA applicants may face separate litigation and separate settlement terms.

Is Vraylar protected by a method-of-use patent?

Yes. Vraylar’s broader patent estate includes treatment-related claims, although the commercial effect of a method patent depends on the approved generic labeling and the availability of indication carve-outs.

References

1. Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited, No. 1:22-cv-00182, U.S. District Court for the District of Delaware, docket materials and dismissal filings.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2015). FDA approves Vraylar to treat schizophrenia and bipolar disorder. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).